reversed-phase HPLC comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2026-03-28. Where a claim depends on a specific study, the study is described rather than over-claimed.
Identity and purity are established with reversed-phase high-performance liquid chromatography, often paired with mass spectrometry for confirmation of the expected mass. Peptide mapping after enzymatic digestion verifies the primary sequence and detects substitutions. Size-exclusion chromatography quantifies aggregates and fragments, which are the impurities most often tracked for peptides of this size. Residual solvents, counterions, and water content fall under separate tests described in pharmacopeial chapters. Circular dichroism or nuclear magnetic resonance may be used in research settings to probe secondary structure, though such methods are less common in routine release testing.
Peptide active ingredients of this type are typically supplied as lyophilized powder because the dry form resists hydrolysis during transport. The material is hygroscopic, so vials are usually equilibrated to room temperature before opening to avoid condensation on the solid. Repeated freeze-thaw cycles can promote aggregation and are generally avoided by aliquoting stock into single-use portions. Personnel handling the powder work in controlled environments to limit inhalation of fine particles. Written procedures usually specify these steps rather than leaving them to individual judgment.
Long-term storage of the solid generally relies on temperatures at or below minus twenty degrees Celsius, while short-term working stocks may be held refrigerated. Light exposure is limited because photodegradation can alter side chains over extended periods. Solutions prepared for analysis are less stable than the dry powder and are typically used within the same working day. Buffer choice matters, since some aqueous conditions favor deamidation or oxidation at specific residues. Stability data are usually generated under defined accelerated conditions and then extrapolated with stated assumptions.
Identity and purity assessment of tirzepatide relies primarily on reversed-phase high-performance liquid chromatography coupled with ultraviolet detection. Mass spectrometry, often in electrospray ionization mode, confirms the molecular mass and detects sequence-related impurities. Peptide mapping after enzymatic digestion provides residue-level confirmation of the backbone. Each method addresses a different question: chromatography for purity and related substances, mass measurement for identity, and mapping for sequence fidelity. No single technique covers all three.
Research and analytical settings increasingly require documentation of peptide origin and chain of custody. Certificate of analysis documents typically report purity by chromatographic area, mass confirmation, appearance, and residual solvent or counterion content. Independent verification by an accredited laboratory is common when a material will be used in a regulated study. Open questions remain about how well compendial methods transfer between laboratories, and about which impurity thresholds are meaningful for materials not intended for clinical use.
| Property | Value | Notes |
|---|---|---|
| Typical supplied form | Lyophilized powder | Hygroscopic, seal promptly after opening |
| Long-term storage temperature | At or below minus 20 C | Protect from repeated freeze-thaw |
| Working solution stability | Hours when refrigerated | Use within the same working day |
| Primary purity method | Reversed-phase HPLC | Often paired with mass spectrometry |
| Aggregate measurement | Size-exclusion chromatography | Reports high-molecular-weight species |
Development began in the 2010s, when researchers modified a GIP-based scaffold to add GLP-1 activity and then attached the fatty diacid to lengthen its half-life. Clinical evaluation proceeded through large phase 3 programmes in type 2 diabetes and in obesity, and regulators in the United States cleared the compound for type 2 diabetes in 2022 and for chronic weight management in 2023. Several cardiovascular and metabolic outcome studies are still reporting, so the picture of long-term benefit and risk is incomplete. Approvals in other regions followed on different timelines.
Tirzepatide is a synthetic peptide of 39 amino acids that carries a C20 fatty diacid side chain attached through a linker. Its molecular formula is C225H348N48O68, and its molecular weight is about 4813 daltons. The compound belongs to the incretin mimetic class and is administered by subcutaneous injection. The fatty acid chain promotes binding to serum albumin, which slows renal clearance and extends the circulation time of the molecule. It was identified during screening of sequences derived from glucose-dependent insulinotropic polypeptide.
Structural work on the molecule centers on a C20 fatty diacid moiety attached through a linker to the peptide backbone. This side chain promotes reversible binding to serum albumin, which slows renal clearance and supports a prolonged action profile. The peptide backbone incorporates aminoisobutyric acid substitutions that limit recognition by digestive enzymes. Together these modifications produce a molecule that is stable enough for subcutaneous delivery but still dependent on careful manufacturing control. Analytical characterization of the active pharmaceutical ingredient typically follows the conventions used for other synthetic peptides.
Tirzepatide is a synthetic peptide composed of 39 amino acids. It acts as a dual agonist at two incretin receptors, the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. The molecule was designed by modifying the native sequence of glucose-dependent insulinotropic polypeptide to improve metabolic stability and extend its circulation time. Its structure includes several non-natural amino acid residues and a fatty acid side chain. These features distinguish it from earlier single-receptor incretin analogs studied in the same period.
Choosing a software tool for structural alignment can be a challenge due to the large variety of available packages that differ significantly in methodology and reliability. A partial solution to this problem was presented in and made publicly accessible through the ProCKSI webserver. A more complete list of currently available and freely distributed structural alignment software can be found in structural alignment software. Properties of some structural alignment servers and software packages are summarized and tested with examples at Structural Alignment Tools in Proteopedia.Org.
== Analysis == A mass spectrometer is typically utilized in one of two ways: full scan or selective ion monitoring (SIM). The typical GC–MS instrument is capable of performing both functions either individually or concomitantly, depending on the setup of the particular instrument. The primary goal of instrument analysis is to quantify an amount of substance. This is done by comparing the relative concentrations among the atomic masses in the generated spectrum. Two kinds of analysis are possible, comparative and original. Comparative analysis essentially compares the given spectrum to a spectrum library to see if its characteristics are present for some sample in the library. This is best performed by a computer because there are a myriad of visual distortions that can take place due to variations in scale. Computers can also simultaneously correlate more data (such as the retention times identified by GC), to more accurately relate certain data. Deep learning was shown to lead to promising results in the identification of VOCs from raw GC–MS data. Another method of analysis measures the peaks in relation to one another. In this method, the tallest peak is assigned 100% of the value, and the other peaks being assigned proportionate values. All values above 3% are assigned. The total mass of the unknown compound is normally indicated by the parent peak. The value of this parent peak can be used to fit with a chemical formula containing the various elements which are believed to be in the compound.
== Diagnosis == The diagnosis of a migraine is based on signs and symptoms. A headache calendar is a useful diagnostic tool for tracking the date, duration, and symptoms of headaches. Migraines can be classified by whether the patient experiences an aura (MA) or not (MO) and headache frequency (episodic or chronic). According to the International Classification of Headache Disorders (ICHD-3), migraine diagnosis is primarily clinical and based on identifying characteristic patterns of headache features and associated symptoms rather than laboratory or imaging findings. Neuroimaging tests are not necessary to diagnose migraine, but may be used to find other causes of headaches in those whose examination and history do not confirm a migraine diagnosis. The American Headache Society's guideline recommends neuroimaging only when "red-flag" symptoms or abnormal neurological findings are present, noting that routine imaging is unnecessary for patients who already meet clinical criteria for migraine. The diagnosis of migraine without aura, according to the International Headache Society, can be made according to the "5, 4, 3, 2, 1 criteria", which is as follows:
The hats of the Australian Light Horse are decorated with emu feather plumes. Trademarks of early Australian companies using the emu included Webbenderfer Bros frame mouldings (1891), Mac Robertson Chocolate and Cocoa (1893), Dyason and Son Emu Brand Cordial Sauce (1894), James Allard Pottery Wares (1906), and rope manufacturers G. Kinnear and Sons Pty. Ltd. still use it on some of their products. There are around six hundred gazetted places in Australia with "emu" in their title, including mountains, lakes, hills, plains, creeks and waterholes. During the 19th and 20th centuries, many Australian companies and household products were named after the bird. In Western Australia, Emu beer has been produced since the early 20th century and the Swan Brewery continues to produce a range of beers branded as "Emu". The quarterly peer-reviewed journal of the Royal Australasian Ornithologists Union, also known as Birds Australia, is entitled Emu: Austral Ornithology. The comedian Rod Hull featured a wayward emu puppet in his act for many years and the bird returned to the small screen in the hands of his son Toby after the puppeteer's death in 1999. In 2019, American insurance company Liberty Mutual launched an advertising campaign that features LiMu Emu, a CGI-rendered emu. The animal sanctuary, Alveus Sanctuary, has an emu named Stompy. He was their first animal ambassador, after being hand raised by the Sanctuary's founder. He is known for "giving hugs" to guests at Alveus, including Ludwig, Jaiden Animations, Jack Manifold, Hasan Piker, and Valkryae.
Sources: en.wikipedia.org
Water soluble drugs might form eutectic mixtures and not freeze adequately, so dose is limited to 60 mg and the maximum drug limit is 400 mg for water insoluble drug as large particle sizes might present sedimentation problems during manufacture.
It was proposed to expand the list of the nine hallmarks of aging with five more. Saudi Arabia has started a not-for-profit organization called "the Hevolution Foundation" with budget $1 billion per year for developing anti-aging technology.
== History == Since its discovery in 1967, serine protease DPP-4 has been a popular subject of research. Inhibitors of DPP-4 have long been sought as tools to elucidate the functional significance of the enzyme. The first inhibitors were characterized in the late 1980s and 1990s. Each inhibitor was important to establish an early structure activity relationship (SAR) for subsequent investigation. The inhibitors fall into two main classes, those that interact covalently with DPP-4 and those that do not. DPP-4 is a dipeptidase that selectively binds substrates that contain proline at the P1-position, thus many DPP-4 inhibitors have 5-membered heterocyclic rings that mimic proline, e.g. pyrrolidine, cyanopyrrolidine, thiazolidine and cyanothiazolidine. These compounds commonly form covalent bonds to the catalytic residue Ser630. In 1994, researchers from Zeria Pharmaceuticals unveiled cyanopyrrolidines with a nitrile function group that was assumed to form an imidate with the catalytic serine. Concurrently other DPP-4 inhibitors without a nitrile group were published but they contained other serine-interacting motifs, e.g. boronic acids, phosphonates or diacyl hydroxylamines. These compounds were not as potent because of the similarity of DPP-4 and prolyl oligopeptidase (PEP) and also suffered from chemical instability. Ferring Pharmaceuticals filed for patent on two cyanopyrrolidine DPP-4 inhibitors, which they published in 1995. These compounds had excellent potency and improved chemical stability. In 1995, Edwin B.
=== Normal hemoglobins === Embryonic HbE Gower 1 (ζ2ε2) HbE Gower 2 (α2ε2) HbE Portland I (ζ2γ2) HbE Portland II (ζ2β2) HbE Portland III (ζ2δ2) Fetal HbF/Fetal (α2γ2) HbA (α2β2) Adult HbA (α2β2) HbA2 (α2δ2) HbF/Fetal (α2γ2)
== Causes == Myxedema coma represents an extreme or decompensated form of hypothyroidism. Most cases occur in patients who have been previously diagnosed with hypothyroidism, yet in some cases, hypothyroidism may not have been previously identified. Common precipitating factors of myxedema coma include:
Sources: en.wikipedia.org
The Kulturkampf had reinforced the Catholic character of the Centre Party, but even during it Ludwig Windthorst had defended the party against Bismarck's accusation of being a "denominational party" in describing the Centre as "a political party with a comprehensive political programme and open to anyone, who accepts it". However, few Protestants took up this offer and the Centre remained, by the composition of its members, politicians and voters, an essentially Catholic party. Loyal to the Pope in church matters, the Centre party steered a course independent of the Holy See on secular matters. This became apparent in the "septennat dispute" of 1886. Since the Centre Party rejected Bismarck's military budget, the Chancellor negotiated with the Holy See and promised to abolish some Kulturkampf-related laws and to support the Pope in the Roman question, if the Vatican persuaded the Centre Party to accept his bill. Despite this agreement, the Centre Party rejected the budget and Bismarck called new elections. He also published the letters with the Vatican, intending to drive a wedge between Catholic voters loyal to the Pope and the Centre Party with the slogan: "The Pope against the Centre!" Windhorst managed to avert this by reaffirming the Party's autonomy, which the Pope had accepted, and by interpreting the published letters as expressions of papal confidence in the party.
=== Growth conditions === Optimal growth occurs between 30 and 40 °C in the presence of oxygen and 10% NaCl. However, some strains can grow at temperatures that range between 18 and 45 °C. Growth at 15 °C or 15% NaCl is poor or absent.
==== Distribution ==== Mescaline is distributed to the liver, spleen, and kidneys at many times higher levels than blood or brain based on animal studies. It is said that a great proportion of mescaline is combined with hepatic proteins, which is said to delay its onset and elimination half-life. The exact portion bound to plasma proteins seems to be unknown, but appears to be minimal. Mescaline appears to have relatively poor blood–brain barrier permeability due to its low lipophilicity. However, it is still able to cross into the central nervous system and produce psychoactive effects at sufficiently high doses. The poor central permeability of mescaline appears to be responsible for its delayed onset of effects and is also thought to contribute to its low potency.
== Products in development == As of September 2014, Eurogentec Biologics was developing a vaccine against bilharziosis called Bilhvax in partnership with INSERM and researchers from the Pasteur Institute; the vaccine candidate was starting Phase III trials at that time.
==== United States ==== The US Food and Drug Administration (FDA) considers safe beverages containing less than 0.02% caffeine; but caffeine powder, which is sold as a dietary supplement, is unregulated. It is a regulatory requirement that the label of most prepackaged foods must declare a list of ingredients, including food additives such as caffeine, in descending order of proportion. However, there is no regulatory provision for mandatory quantitative labeling of caffeine, (e.g., milligrams caffeine per stated serving size). There are a number of food ingredients that naturally contain caffeine. These ingredients must appear in food ingredient lists. However, as is the case for "food additive caffeine", there is no requirement to identify the quantitative amount of caffeine in composite foods containing ingredients that are natural sources of caffeine. While coffee or chocolate are broadly recognized as caffeine sources, some ingredients (e.g., guarana, yerba maté) are likely less recognized as caffeine sources. For these natural sources of caffeine, there is no regulatory provision requiring that a food label identify the presence of caffeine nor state the amount of caffeine present in the food. The FDA guidance was updated in 2018.
Sources: en.wikipedia.org
Water promotes hydrolysis and deamidation, so removing it slows degradation during transport and storage. The dry solid is also less prone to microbial growth than a solution. Reconstitution is therefore performed close to the point of use.
Reversed-phase high-performance liquid chromatography is the standard method for purity and related substances. It separates the main peak from deletion sequences and oxidation products. Mass spectrometry is frequently used alongside it to confirm molecular identity.
Aggregates, truncated sequences, and oxidation products receive the most attention. Size-exclusion chromatography covers aggregates, while reversed-phase methods resolve many chemical variants. Limits are set according to the route of administration and the expected exposure.
The peptide backbone and its fatty acid side chain are susceptible to degradation at elevated temperatures. Refrigeration slows hydrolysis, oxidation, and aggregation processes. Labeled storage ranges reflect stability data generated under defined conditions.